Selinexor in Combination With Chemotherapy to Treat Relapsed/Refractory Multiple Myeloma Patients
Latest Information Update: 22 Jan 2024
Price :
$35 *
At a glance
- Drugs Cyclophosphamide (Primary) ; Dexamethasone (Primary) ; Doxorubicin liposomal (Primary) ; Selinexor (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 12 Dec 2023 Interim Results (n= As of July 26, 2023, n=44) assessing safety and efficacy of of Selinexor, Dexamethasone and Chemotherapy Drugs in Relapsed/ Refractory Multiple Myeloma presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 15 Jun 2023 Results safety analysis (n=14; as of data cutoff: 11 Feb 2023) presented at the 28th Congress of the European Haematology Association
- 15 Jun 2023 Results of interim analysis (As of Feb 24th 2023, n=28) assessing the preliminary efficacy, safety, and tolerability of the combination of Xd plus chemotherapy drugs in pts with RRMM presented at the 28th Congress of the European Haematology Association